• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

eFoodSafety.Com, Inc. Subsidiary, Knock-Out Technologies, Ltd. Announces Exclusive Manufacturing Agreement

Posted on: Wednesday, 14 September 2005, 12:00 CDT

Robert Bowker, President of Knock-Out Technologies, Ltd., a wholly-owned subsidiary of eFoodSafety.com, Inc. (OTCBB: EFSF), announced today that Knock-Out Technologies signed an exclusive manufacturing agreement with NutraLab, Inc.

NutraLab, Inc. will be the exclusive manufacturer of Knock-Out's products, initially the Big Six Plus Germicidal and the Anthrax Sporicidal. NutraLab will work with the company on packaging, formulation, and a delivery system for its products.

"We continue to get everything ready as we await EPA Registration on the Big Six Germicidal and prepare the Anthrax Sporicidal for EPA Registration. Our approach is to deal with the most professional organizations so that our products are well received when we launch them," stated Patricia Ross-Gruden, President and CEO of eFoodSafety.com, Inc.

NutraLab, Inc. has its own large, well-established portfolio of proprietary formulations and is committed to using only quality ingredients in their clients' products.

"We are pleased to align ourselves with a cutting-edge and proven laboratory, such as NutraLab. They will prove to be an invaluable asset as we begin to work on our next generation of innovative products in the coming months," added Mrs. Ross-Gruden.

About eFoodSafety.com, Inc.

eFoodSafety.com, Inc. is dedicated to improving food and health conditions around the world through its innovative technologies. The company's Knock-Out Technologies, Ltd. subsidiary has developed an environmentally safe sporicidal product formulated entirely of food-grade components that eradicates anthrax and a germicidal product that kills six major bacteria: E-coli, Listeria, Pseudomonas, Salmonella, Staphylococcus, and Streptococcus, and avian influenza. The sporicidal product has completed its final efficacy laboratory study requisite for EPA licensure; in the study, it eradicated both Clostridium Sporogenes and Bacillus Subtilis with 100% efficacy on both hard and porous surfaces. The company's recently announced acquisition of MedElite, Inc. is expected to provide recurring revenue to the company. MedElite, Inc. distributes clinically proven products to physicians who then prescribe the products for their patients. It is the exclusive U.S. and Worldwide distributor of the Talsyn(TM)-CI/bid Scar Cream that has been clinically proven to facilitate and improve the appearance, redness and strength of scars (www.talsyn.com).

Safe Harbor Forward-Looking Statements

Statements contained in this release that are not strictly historical are "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933 as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements are made based on information available as of the date hereof, and the company assumes no obligation to update such forward-looking statements. Editors and investors are cautioned that such forward-looking statements invoke risk and uncertainties and the company's actual results may differ from these forward-looking statements. Such risks and uncertainties include but are not limited to demand for the company's products and services, our ability to continue to develop markets, general economic conditions, our ability to secure additional financing for the company and other factors that may be more fully described in reports to shareholders and periodic filings with the Securities and Exchange Commission.

Source: Business Wire

More News in this Category